EUVIMEDEUVIMED entdecken
Open Access · CC0

Novel modelling approaches to predict the role of antivirals in reducing influenza transmission

Jason Asher, Annabelle Lemenuel-Diot iD, Matthew Clay iD, David P Durham, Luis Mier-Y-Teran-Romero iD, Carlos J Arguello, Sebastien Jolivet, Diana Y Wong, Klaus Kuhlbusch, Barry Clinch, Jean-Eric Charoin

PLOS Computational Biology · 06.01.2023 · 19 (1) · e1010797

DOI: 10.1371/journal.pcbi.1010797 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Computational Biology, online erschienen am 06.01.2023. Verfasst von Jason Asher und 10 weiteren Autor:innen. Beteiligte Einrichtung: Leidos, Reston, Virginia, United States of America. Hauptthemen laut MEDLINE: Influenza, Human, Thiepins. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: F. Hoffmann-La Roche, Office of Public Health Preparedness and Response, Biomedical Advanced Research and Development Authority.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To aid understanding of the effect of antiviral treatment on population-level influenza transmission, we used a novel pharmacokinetic–viral kinetic transmission model to test the correlation between nasal viral load and infectiousness, and to evaluate the impact that timing of treatment with the antivirals oseltamivir or baloxavir has on influenza transmission. The model was run under three candidate profiles whereby infectiousness was assumed to be proportional to viral titer on a natural-scale, log-scale, or dose–response model. Viral kinetic profiles in the presence and absence of antiviral treatment were compared for each individual (N = 1000 simulated individuals); subsequently, viral transmission mitigation was calculated. The predicted transmission mitigation was greater with earlier administration of antiviral treatment, and with baloxavir versus oseltamivir. When treatment was initiated 12–24 hours post symptom onset, the predicted transmission mitigation was 39.9–56.4% for baloxavir and 26.6–38.3% for oseltamivir depending on the infectiousness profile. When treatment was initiated 36–48 hours post symptom onset, the predicted transmission mitigation decreased to 0.8–28.3% for baloxavir and 0.8–19.9% for oseltamivir. Model estimates were compared with clinical data from the BLOCKSTONE post-exposure prophylaxis study, which indicated the log-scale model for infectiousness best fit the observed data and that baloxavir affords greater reductions in secondary case rates compared with neuraminidase inhibitors. These findings suggest a role for baloxavir and oseltamivir in reducing influenza transmission when treatment is initiated within 48 hours of symptom onset in the index patient.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza, HumanThiepinsHumansAntiviral AgentsOseltamivirOxazinesPyridinesTriazinesDibenzothiepinsMorpholinesPyridones

Substanzen

Antiviral AgentsOseltamivirOxazinesPyridinesThiepinsTriazinesbaloxavirDibenzothiepinsMorpholinesPyridones

Autor:innen und Institutionen

  • Leidos, Reston, Virginia, United States of America.
  • Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Office of the Assistant Secretary for Preparedness and Response, U.S Department of Health and Human Services, Washington, District of Columbia, United States of America.
  • F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Roche Products Ltd., Welwyn Garden City, United Kingdom.

ORCID-Profile: Annabelle Lemenuel-Diot, Matthew Clay, Luis Mier-Y-Teran-Romero

Förderung

  • F. Hoffmann-La Roche
  • Office of Public Health Preparedness and Response
  • Biomedical Advanced Research and Development Authority

Zitieren

APA

Asher, J., Lemenuel-Diot, A., Clay, M., Durham, D. P., Mier-Y-Teran-Romero, L., Arguello, C. J., Jolivet, S., Wong, D. Y., Kuhlbusch, K., Clinch, B., & Charoin, J. E. (2023). Novel modelling approaches to predict the role of antivirals in reducing influenza transmission. PLOS Computational Biology, 19(1), e1010797. https://doi.org/10.1371/journal.pcbi.1010797

Vancouver

Asher J, Lemenuel-Diot A, Clay M, Durham DP, Mier-Y-Teran-Romero L, Arguello CJ, et al. Novel modelling approaches to predict the role of antivirals in reducing influenza transmission. PLOS Computational Biology. 2023;19(1):e1010797. doi:10.1371/journal.pcbi.1010797

BibTeX
@article{Asher2023,
  author = {Asher, Jason and Lemenuel-Diot, Annabelle and Clay, Matthew and Durham, David P and Mier-Y-Teran-Romero, Luis and Arguello, Carlos J and Jolivet, Sebastien and Wong, Diana Y and Kuhlbusch, Klaus and Clinch, Barry and Charoin, Jean-Eric},
  title = {Novel modelling approaches to predict the role of antivirals in reducing influenza transmission},
  journal = {PLOS Computational Biology},
  year = {2023},
  volume = {19},
  number = {1},
  pages = {e1010797},
  doi = {10.1371/journal.pcbi.1010797}
}
Kostenlos starten →